Kelly A. Schick's most recent trade in C4 Therapeutics Inc was a trade of 84,700 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 13, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| C4 Therapeutics Inc | Kelly A. Schick | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 84,700 | 84,700 | - | - | Stock Option (Right to Buy) | |
| C4 Therapeutics Inc | Kelly A. Schick | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 56,500 | 111,253 | - | 0 | Common Stock | |
| C4 Therapeutics Inc | Kelly A. Schick | Chief People Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.18 per share. | 13 Feb 2025 | 2,368 | 108,885 | - | 3.2 | 7,530 | Common Stock |
| C4 Therapeutics Inc | Kelly A. Schick | Chief People Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.20 per share. | 13 Feb 2025 | 1,735 | 54,753 | - | 3.2 | 5,552 | Common Stock |
| C4 Therapeutics Inc | Kelly A. Schick | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2024 | 3,750 | 57,590 | - | - | Common Stock | |
| C4 Therapeutics Inc | Kelly A. Schick | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2024 | 3,750 | 10,500 | - | - | Performance Restricted Stock Units | |
| C4 Therapeutics Inc | Kelly A. Schick | Chief People Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.04 per share. | 07 Nov 2024 | 1,102 | 56,488 | - | 6.0 | 6,656 | Common Stock |
| C4 Therapeutics Inc | Kelly A. Schick | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2024 | 2,250 | 14,250 | - | - | Performance Restricted Stock Units | |
| C4 Therapeutics Inc | Kelly A. Schick | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2024 | 2,250 | 54,501 | - | - | Common Stock | |
| C4 Therapeutics Inc | Kelly A. Schick | Chief People Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.36 per share. | 16 Sep 2024 | 661 | 53,840 | - | 6.4 | 4,204 | Common Stock |